Capricor

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Capricor and other ETFs, options, and stocks.

About CAPR

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. 

CEO
Linda Marbán
CEOLinda Marbán
Employees
231
Employees231
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1996
Founded1996
Employees
231
Employees231

CAPR Key Statistics

Market cap
441.88M
Market cap441.88M
Price-Earnings ratio
-2.87
Price-Earnings ratio-2.87
Dividend yield
—
Dividend yield—
Average volume
7.29M
Average volume7.29M
High today
$8.94
High today$8.94
Low today
$1.35
Low today$1.35
Open price
$8.16
Open price$8.16
Volume
20.06M
Volume20.06M
52 Week high
$40.37
52 Week high$40.37
52 Week low
$1.35
52 Week low$1.35

Stock Snapshot

Capricor(CAPR) stock is priced at $1.63, giving the company a market capitalization of 441.88M. It carries a P/E multiple of -2.87.

On 2026-11-21, Capricor(CAPR) stock moved within a range of $1.35 to $8.94. With shares now at $1.63, the stock is trading +20.7% above its intraday low and -81.8% below the session's peak.

Trading volume for Capricor(CAPR) stock has reached 20.06M, versus its average volume of 7.29M.

Over the past 52 weeks, Capricor(CAPR) stock has traded between a high of $40.37 and a low of $1.35.

Over the past 52 weeks, Capricor(CAPR) stock has traded between a high of $40.37 and a low of $1.35.

CAPR News

Investing.com 5h
Capricor shares plunge 80% as FDA cites trial violations in drug rejection - Investing.com

...

Capricor shares plunge 80% as FDA cites trial violations in drug rejection - Investing.com
Seeking Alpha 3d
Capricor, Regenxbio among gainers as White House pulls Trump’s FDA pick

Capricor, Regenxbio among gainers as White House pulls Trump’s FDA pick Nov 18, 2026, 9:06 AM ET Capricor Therapeutics, Inc. (CAPR) Stock, RGNX Stock, REPL Stoc...

Capricor, Regenxbio among gainers as White House pulls Trump’s FDA pick
Benzinga 3d
Capricor Stock in Focus Ahead of FDA Decision on Duchenne Therapy Deramiocel

Capricor Therapeutics Inc. (NASDAQ:CAPR) shares are in the spotlight Wednesday as investors position ahead of the FDA’s decision on deramiocel, the company’s ce...

Capricor Stock in Focus Ahead of FDA Decision on Duchenne Therapy Deramiocel

Analyst ratings

56%

of 9 ratings
Buy
55.6%
Hold
44.4%
Sell
0%

More CAPR News

Benzinga 4d
Capricor Stock Rises: What's Going On?

Capricor Therapeutics Inc. (NASDAQ:CAPR) shares are rising Tuesday. Traders seemingly position ahead of the FDA’s pending decision on its Duchenne muscular dyst...

Capricor Stock Rises: What's Going On?
TipRanks 6d
Capricor Therapeutics Earnings Call Signals Deramiocel Momentum

Capricor Therapeutics, Inc. ((CAPR)) has held its Q3 earnings call. Read on for the main highlights of the call. Capricor Therapeutics delivered a predominantl...

People also own

Based on the portfolios of people who own CAPR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.